trials are being performed in prostate and advanced cervix cancer. 4.2 Posology andadministrationform. The vial corresponding to the chemical conjugate contains the equivalent to 0.9mg of the chemical conjugate EGF-P64K in0.9 mL of saline solution. The vial corresponding to the adjuvant contains 0.8mL of Montanide ISA 51 VG. The mended dose is of 2,4mg ofchemical conjugate EGF-P64k. At the time of use, 0, 8mL of the chemical conjugate are added to the vial containing the adjuvant (Montanide ISA 51), then are mixed until emulsification. From the emulsion, 1,2mL are extracted with asyringe to be injected to the patient in each injection site. A dose consist in 4 injections administered in 4 injection sites (both deltoid and gluteus regions).
全文预览
